Mealey's (July 26, 2019, 1:18 PM EDT) -- WASHINGTON, D.C. — In a July 25 appellant brief, Immunex Corp. maintains that the Patent Trial and Appeal Board erred by not construing “human antibody” as limited to fully human antibodies, thus compelling the Federal Circuit U.S. Court of Appeals to reverse and vacate a final written decision that found all challenged claims of a patent obvious (Immunex Corp. v. Sanofi-Aventis US LLC, et al., Nos. 19-1749, -1777, Fed. Cir.)....